comparemela.com

Latest Breaking News On - Biosynex - Page 1 : comparemela.com

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc

STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project

New yorkUnited statesIllkirch graffenstadenGilles broqueletLarry abensurChembio diagnostics incExchange commissionMerci merger sub incSecurities transfer corporationAlliance advisorsProject merci merger subChembio diagnosticsNew york cityTransfer corporationTender offer statementInformation agent

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales,

United statesIllkirch graffenstadenRichardl eberlyPhilip taylorGilles broqueletLarry abensurKl gatesCraig hallum capital groupExchange commissionChembio diagnostics incGilmartin groupSecurities exchangeWhite caseComplementary technologiesProduct portfoliosMarket opportunities expected

BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S A

DJ BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A. BIOSYNEX SA BIOSYNEX SA: Extension of the distribution agreement between Credo

United kingdomIllkirch graffenstadenWinston wong jrLarry abensurEnglish companyCredo diagnostics biomedical pte ltdNews serviceFrench regulatory newsCredo diagnosticsPolymerase chain reactionRespiratory syncytial virusClinical performance studiesBridger listing sponsorBroquelet financialDow jones newswires

Theradiag Announces That Biosynex Has Filed a Voluntary Takeover Bid for Its Shares

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, announces that Biosynex (ISIN: FR0011005933 Mnemonic:

Schleswig holsteinFrance generalPierre laurent quentinArthur rouillEconomic committee of theradiagFinancial communications investor relationsRegulatory newsEconomic committeeEuronext growth parisManaging directorCommunications investor relationsLaurent quentin mass

Theradiag: THERADIAG notes the acquisition of a stake in its capital by BIOSYNEX

Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces that it has received yesterday a letter

Schleswig holsteinFrance generalPierre laurentFinancial communications investor relationsRegulatory newsRights issueEuronext growth parisManaging directorCommunications investor relations

vimarsana © 2020. All Rights Reserved.